BHST
BioHarvest Sciences Inc. (BHST) Risks & Opportunities Analysis (2026)
Risks
Negative interest coverage versus direct peers implies earnings are not yet covering financing costs, increasing sensitivity to any demand or margin softness relative to better-capitalized competitors.
A 119-day cash conversion cycle, driven by 145 days of inventory, ties up working capital and can constrain flexibility versus peers with faster inventory turns.
Debt-to-equity near 0.9 leaves BHST more exposed than low-leverage peers if operating conditions weaken, even though net debt is modest on a TTM basis.
A current ratio above 2.0 reduces near-term liquidity risk, but the weak coverage profile means peers with stronger profitability can absorb shocks more easily.
Opportunities
Net debt is slightly negative, giving BHST more balance-sheet flexibility than leveraged peers to support growth, inventory, or customer demand swings.
Current and quick ratios above 2.0 and 1.7, respectively, position BHST better than tighter-liquidity peers to manage working-capital volatility without immediate refinancing pressure.
If inventory normalizes from elevated levels, cash release could improve free cash flow conversion faster than peers with already leaner working-capital profiles.
Relative leverage remains manageable, so any improvement in operating profitability would translate more directly into peer-relative upside because financing drag is currently limited.
Overall Score
BHST’s modest leverage and solid liquidity support peer-relative resilience, but weak interest coverage and heavy working-capital intensity limit upside realization versus stronger operators.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on BioHarvest Sciences Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

